Atea Pharmaceuticals Files Proxy Statement
Ticker: AVIR · Form: DEFA14A · Filed: Mar 26, 2025 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | DEFA14A |
| Filed Date | Mar 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, regulatory
Related Tickers: TEA
TL;DR
Atea Pharma filed its proxy statement (DEFA14A) on 3/26/25, no fee required.
AI Summary
Atea Pharmaceuticals, Inc. filed a DEFA14A on March 26, 2025, indicating it is soliciting material under Rule 14a-12. The filing pertains to their proxy statement and confirms no fee was required for this submission. The company is incorporated in Massachusetts and its fiscal year ends on December 31.
Why It Matters
This filing is a routine but necessary step for public companies to communicate with shareholders regarding important corporate matters, such as annual meetings and voting on proposals.
Risk Assessment
Risk Level: low — This is a standard regulatory filing (DEFA14A) for a public company, not indicating any immediate financial or operational risk.
Key Players & Entities
- Atea Pharmaceuticals, Inc. (company) — Registrant
- 20250326 (date) — Filing Date
- Rule 14a-12 (regulation) — Soliciting Material
- MA (state) — State of Incorporation
- 1231 (date) — Fiscal Year End
FAQ
What type of filing is this DEFA14A for Atea Pharmaceuticals, Inc.?
This DEFA14A is a Definitive Proxy Statement filed by Atea Pharmaceuticals, Inc., and is considered soliciting material under Rule 14a-12.
When was this filing made?
The filing was made on March 26, 2025.
Was there a fee associated with this filing?
No fee was required for this filing.
Where is Atea Pharmaceuticals, Inc. incorporated?
Atea Pharmaceuticals, Inc. is incorporated in Massachusetts (MA).
What is the fiscal year end for Atea Pharmaceuticals, Inc.?
The fiscal year end for Atea Pharmaceuticals, Inc. is December 31 (1231).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 26, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).